Relapsing Panniculitis

Comprehensive Clinical Guide: Relapsing Panniculitis (Weber-Christian Disease)

1. Introduction and Clinical Overview

Relapsing Panniculitis, historically and clinically recognized as Weber-Christian disease, represents a rare, idiopathic, systemic inflammatory disorder characterized by recurring episodes of subcutaneous fat necrosis. It is a subset of the broader panniculitis group, which consists of inflammatory conditions affecting the adipose tissue.

Unlike localized forms of panniculitis, which are often reactive to trauma or localized infection, relapsing panniculitis is categorized as a systemic disease. It frequently involves both cutaneous manifestations—tender, erythematous nodules—and systemic involvement, including fever, malaise, arthralgia, and potential visceral organ inflammation. The condition is notoriously relapsing-remitting, meaning patients experience periods of acute flare-ups interspersed with quiescent intervals.

Due to its multisystemic nature, it requires a multidisciplinary approach involving dermatologists, rheumatologists, and, in cases of visceral involvement, internal medicine specialists.

2. Deep-Dive: Etiology and Pathophysiology

The exact etiology of relapsing panniculitis remains largely elusive, leading to its classification as an idiopathic condition. However, modern research suggests a complex interplay between immunological dysregulation and metabolic triggers.

Mechanisms of Action

The primary pathological event is the inflammation of the lobular adipose tissue. The mechanism is theorized to be an autoimmune-mediated response where the immune system targets adipocytes. Key pathophysiological features include:

• Lymphocytic and Histiocytic Infiltration: The early stages are characterized by an infiltration of lymphocytes, macrophages, and neutrophils into the fat lobules.
• Foamy Macrophages: A hallmark histological finding is the presence of "foamy" macrophages (lipophages) that have ingested lipid debris from necrotic adipocytes.
• Cytokine Cascade: There is an upregulation of pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which perpetuate the inflammatory cycle.
• Fibrosis: In chronic or late-stage lesions, the inflammatory process is replaced by fibrous connective tissue, leading to permanent subcutaneous induration and atrophy.

3. Clinical Indications and Standard Presentation

Relapsing panniculitis typically presents in adults, though it can occur at any age. The clinical presentation is highly variable, but consistent patterns emerge in the majority of cases.

Cardinal Symptoms

1. Cutaneous Nodules: These are the hallmark of the disease. They are typically found on the lower extremities, thighs, and abdomen. They range from 1–5 cm in diameter, are deep-seated, and are tender to palpation.
2. Systemic Symptoms: These often accompany the cutaneous flares and include:
   • High-grade or low-grade fever.
   • Generalized malaise and fatigue.
   • Arthralgia (joint pain) and myalgia (muscle pain).
   • Hepatosplenomegaly in severe, systemic cases.
3. Visceral Involvement: In rare, aggressive forms, the fat necrosis can occur in the mesentery, retroperitoneum, and perirenal fat, potentially leading to organ dysfunction.

Diagnostic Staging/Grading

While there is no universally standardized staging system for Weber-Christian disease, clinicians often grade the severity based on the Systemic Involvement Index:

• Grade I (Localized): Skin nodules only; no fever; no visceral findings.
• Grade II (Systemic - Mild): Skin nodules + low-grade fever + arthralgia.
• Grade III (Systemic - Severe): Skin nodules + high-grade fever + visceral fat involvement (mesenteric/perirenal) + laboratory evidence of organ inflammation.

4. Differential Diagnosis

Because panniculitis can be reactive to many stimuli, the differential diagnosis is extensive. It is critical to rule out "secondary" panniculitis before assigning a diagnosis of idiopathic Relapsing Panniculitis.

• Infectious Panniculitis: Bacterial or fungal infections (e.g., Mycobacterium, Nocardia).
• Erythema Nodosum: Usually septal, not lobular; typically self-limiting and associated with infection or drugs.
• Pancreatic Panniculitis: Associated with pancreatic disease; histologically shows "ghost cells" (anucleated adipocytes).
• Alpha-1 Antitrypsin Deficiency: A genetic condition that mimics relapsing panniculitis; must be ruled out via serum testing.
• Lupus Panniculitis (Profundus): Associated with systemic lupus erythematosus; usually involves the upper arms and face.
• Traumatic Panniculitis: History of physical injury or injection.

5. Diagnostic Testing

Diagnosis is rarely achieved through clinical presentation alone. A multi-modal approach is required.

1. Incisional Skin Biopsy: The gold standard. A deep wedge biopsy (including the full subcutaneous layer) is required. Punch biopsies are often insufficient.
2. Laboratory Panels:
   • CBC: Often shows leukocytosis or leukopenia.
   • ESR/CRP: Elevated markers of systemic inflammation.
   • Alpha-1 Antitrypsin Levels: Essential to rule out deficiency.
   • Liver Function Tests: To assess for systemic visceral involvement.
3. Imaging:
   • MRI: Excellent for visualizing the extent of subcutaneous involvement and identifying deep-seated mesenteric lesions.
   • CT Scan: Utilized if visceral (abdominal/thoracic) involvement is suspected.

6. Risks, Side Effects, and Therapeutic Management

Management focuses on controlling inflammation and preventing the progression to fibrosis and visceral damage.

Therapeutic Approaches

• First-Line: Systemic corticosteroids (Prednisone) are the mainstay for acute flares.
• Second-Line: Immunosuppressants such as Cyclosporine, Azathioprine, or Methotrexate are used for long-term control to spare steroid use.
• Emerging Therapies: TNF-alpha inhibitors (e.g., Infliximab, Etanercept) have shown promise in refractory cases.
• Supportive Care: NSAIDs for pain management and physical therapy for joints affected by systemic inflammation.

Risks and Contraindications

• Steroid Toxicity: Long-term use of corticosteroids carries risks of osteoporosis, diabetes, and infection.
• Immunosuppression: Patients on biologics are at high risk for opportunistic infections.
• Contraindications: Avoid elective surgery on actively inflamed skin, as this can trigger a massive inflammatory flare (pathergy-like phenomenon).

7. Long-Term Prognosis

The prognosis is generally favorable for patients with Grade I or II disease, provided they are managed with appropriate anti-inflammatory protocols. However, the disease is chronic and requires ongoing monitoring. Patients with Grade III visceral involvement face a higher mortality risk if the mesenteric or perirenal inflammation leads to organ failure or bowel obstruction. Regular monitoring of inflammatory markers (ESR/CRP) is mandatory to catch relapses before they become systemic.

8. Massive FAQ Section

1. Is Relapsing Panniculitis a form of cancer?
No. It is an inflammatory, non-malignant condition. However, it is essential to distinguish it from cutaneous T-cell lymphoma, which can sometimes masquerade as panniculitis.

2. Is this condition contagious?
No. It is an internal immune-mediated process and cannot be transmitted to others.

3. Why do I need a deep wedge biopsy?
The pathology of panniculitis occurs deep in the fat layer. Small surface biopsies often miss the diagnostic inflammatory patterns located in the deeper septa and lobules.

4. What is the role of diet in managing this condition?
While no specific diet cures the disease, an anti-inflammatory diet (low in processed sugars, high in Omega-3s) may assist in managing the overall systemic inflammatory load.

5. How long do the nodules last?
Untreated nodules can last weeks to months. With appropriate treatment, they typically resolve within 1–3 weeks, though they may leave behind areas of fat atrophy (dents in the skin).

6. Can I exercise during a flare?
Strenuous exercise may increase pain and local inflammation. Gentle activity is encouraged, but patients should rest during acute, systemic flares.

7. Are there genetic links?
Most cases are sporadic. However, because it can be confused with Alpha-1 Antitrypsin Deficiency, genetic testing or serum protein testing is often performed to rule out a hereditary component.

8. What is the most dangerous complication?
The most severe complication is visceral involvement, specifically when the fat surrounding the intestines or kidneys becomes inflamed, leading to potential obstruction or renal impairment.

9. Will the skin ever look normal again?
In mild cases, yes. In chronic cases where significant fat necrosis has occurred, the skin may remain indented or scarred (lipoatrophy).

10. Do I need to see a specialist for life?
Yes. Because the disease is "relapsing," you need a long-term relationship with a rheumatologist or dermatologist to manage flares immediately as they arise, minimizing the risk of permanent scarring or systemic progression.

Summary Checklist for Clinical Staff

• [ ] Rule out infection: Perform blood cultures and skin cultures.
• [ ] Rule out A1AT deficiency: Order serum Alpha-1 Antitrypsin levels.
• [ ] Perform Deep Biopsy: Ensure the sample includes the full depth of the subcutis.
• [ ] Baseline Labs: ESR, CRP, CBC, LFTs, and Renal function.
• [ ] Monitor for Systemic Symptoms: Assess for fever, hepatosplenomegaly, and joint pain at every visit.